Physician profile
Sherry Dekeyser
NPI 1518913540
$4,846.24
in general payments reported to CMS, 2019-2025
24 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $597 · 2021: $731 · 2022: $1,040 · 2023: $1,097 · 2024: $487 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,914.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,203.12 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $448.82 | 2019-2024 | Rexulti |
| Lundbeck LLC | $436.65 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $348.95 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $342.73 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $317.46 | 2021-2023 | Lybalvi |
| Janssen Pharmaceuticals, INC | $196.93 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $196.78 | 2019-2023 | Ingrezza |
| Allergan, INC. | $187.65 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $170.17 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $169.71 | 2022-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $148.97 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $119.74 | 2020-2023 | Austedo |
| Bausch Health US, LLC | $97.17 | 2021-2023 | Aplenzin |
| Almatica Pharma LLC | $86.08 | 2021-2023 | Loreev Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.95 | 2022-2023 | |
| Corium, LLC | $61.26 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $60.59 | 2022 | |
| Biogen, INC. | $40.97 | 2023 | |
| Eisai INC. | $37.74 | 2020 | |
| Neos Therapeutics, LP | $34.16 | 2019-2024 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $30.50 | 2023 | Quviviq |
| Noven Pharmaceuticals, INC. | $21.09 | 2024 | Xelstrym |
| Shire North American Group INC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Dekeyser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.